Aurobindo Pharma’s net profit for the fourth quarter ended March 31, 2012 fell 33.70% to Rs 87.91 crore as compared to Rs 132.59 crore for the quarter ended March 31, 2011. However, the total income has increased by 3.51% to Rs 1100.41 crore for the quarter under review from Rs 1063.10 crore for the corresponding quarter of the previous year.
For the year ended March 31, 2012, the company reported a net loss of Rs 42.61 crore as compared to net profit of Rs 593.80 crore for the previous year. However, the company’s total income has increased by 3.74% to Rs 4300.51 crore for the year from Rs 4145.63 crore in the previous year
Aurobindo Pharma is currently trading at Rs 111.75, up by 1.25 points or 1.13% from its previous closing of Rs 110.50 on the BSE.
The scrip opened at Rs 110.45 and has touched a high and low of Rs 112.55 and Rs 107.85 respectively. So far 87301 shares were traded on the counter.
The BSE group 'A' stock of face value Re 1 has touched a 52 week high of Rs 188.85 on 27-Jul-2011 and a 52 week low of Rs 80.35 on 18-Nov-2011.
Last one week high and low of the scrip stood at Rs 118.30 and Rs 106.80 respectively. The current market cap of the company is Rs 3259.10 crore.
The promoters holding in the company stood at 54.76% while Institutions and Non-Institutions held 29.39% and 15.85% respectively.
On consolidated basis, the Group’s net loss after taxes and minority interest stood at Rs 123.51 crore for the year under review as compared to net profit of Rs 563.45 crore for the period ago. However, its total income has increased by 5.60% to Rs 4652.10 crore for the year ended March 31, 2012 from Rs 4405.36 crore in the previous year.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |